Data readout from the maintenance dosing study of VK2735, the company’s investigational obesity candidate, is expected in the ...
While those timelines might not seem exciting, investors should note that Viking is due to release results from an extremely ...
Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Most investors currently see the glass on this stock as being half-empty. Analysts, however, still view the glass as at least half-full.
Zacks Investment Research on MSN
Viking Therapeutics, Inc. (VKTX) exceeds market returns: Some facts to consider
In the latest close session, Viking Therapeutics, Inc. (VKTX) was up +1.53% at $29.78. The stock outpaced the S&P 500's daily gain of 0.41%. On the other hand, the Dow registered a gain of 1.73%, and ...
Investors in Viking Therapeutics Inc (Symbol: VKTX) saw new options begin trading this week, for the May 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to ...
Investors appear disappointed with Viking Therapeutics Inc.’s (NASDAQ:VKTX) data from its Phase 2 trial of an obesity pill. Participants receiving once-daily doses of oral VK2735 demonstrated a mean ...
Investors in Viking Therapeutics Inc (Symbol: VKTX) saw new options become available today, for the December 26th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...
Investors with a lot of money to spend have taken a bullish stance on Viking Therapeutics (NASDAQ:VKTX). And retail traders should know. We noticed this today when the positions showed up on publicly ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results